| 摘要 |
FIELD: medicine.SUBSTANCE: invention can be used to predict thrombocytopenia in the patients suffering chronic hepatitis C (CHC) as a result of a combination antiviral therapy (CAT). Before the CAT starts, viral load (VL, IU/ml) is determined in the CHC patients. A fibrosis level is shown by indirect liver fibroelastography (F, kPa). A pre-CAT blood thrombocyte count is determined (Thr, x10/l). The received data are used to derive a predicted minimum blood thrombocyte count (Thr, x10/l) by multiple linear regression. If Thr?150.0x10/l, the risk of thrombocytopenia progression in the CHC patients receiving the CAT. If Thrfalls within the range from 75.0x10/l to 150.0x10/l enables supposing progression of mild thrombocytopenia; Thrfrom 50.0x10/l to 75.0x10/l shows moderate thrombocytopenia, and Thr<50.0x10/l - severe thrombocytopenia.EFFECT: method enables accurate, fast and simple prediction of thrombocytopenia progression by the integrated assessment of the most important factors of thrombocytopenia.1 tbl, 2 ex |
